P0051 Immunomodulator effect of black cumin seed oil (BCO) in the inhibition of breast cancer carcinogenesis in Dimenthylbenzantracene (DMBA)-induced SD rats

Abstract

Background Dimenthylbenzantracene (DMBA) suppresses bone marrow and splenocyte activity, and consequently decreases T lymphocyte, CD4Th, and CD8/CTL proliferation activity. CD4Th, CD4CD25Treg, and cytolytic T lymphocytes have an important role in immunosurveillance on carcinogenesis. Methods A study was conducted to eludcidate the chemopreventive and immunomodular effects of black cumin seed oil (BCO) administration, before and during DMBA induction (10 × 20 mg/KgBW over 5 weeks), in 80 SD rats. The test animals were divided into eight groups of ten mice. Group 1 was the normal control group; groups 2, 3 and 4 were treated with 6.85, 13.7, and 137 mg/kgBW/day BCO, respectively, and induced with DMBA; group 5 was positive control I (thymoquinone group); group 6 was positive control II (tamoxifen group); group 7 was the sick group (DMBA group); and group 8 was the solvent control group. All experimental and control groups were induced with 20 mg/kgBW DMBA, twice a week for 5 weeks. In week 27 a dissection and data collection were conducted. The nodule formation was observed starting from week 10 to week 27. The level of IFNγ was measured with ELISA. The calculation of the number of lymphocyte CD4Th, CD8 (CTL), and CD4CD25Treg of peripheral blood was conducted by flow cytometer. The chemopreventive effect was specified by determining the nodule incidence, the time of nodule formation, and histopathology image. The difference of the mean among all groups was measured by one-way ANOVA. Subsequently, the average difference between the test groups was tested and the LSD test was conducted. Findings Administration of BCO before and during induction with DMBA 10 × 20 mg/kgBW/day for 5 weeks decreased nodule formation and nodule number, increased the number of CD8 and CD4Th cytotoxic lymphocytes, and decreased the percentage of CD4CD25Treg in SD rats. 6.85 mg/kgBW/day dosage of BCO has the same chemopreventive and immunomodulator effect as the 68.5 mg/kgBW/day dosage but it is safer. Interpretation BCO administration of 6.85 mg/kgBW/day has chemopreventive and immunoprotective effects on DMBA-induced SD rats with breast cancer carcinogenesis.